SanBio and Sunovion Pharmaceuticals Inc., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. is conducting a Phase 2b clinical trial study in 2015 to further evaluate the safety and efficacy of SB623 cell therapy in subjects with chronic motor deficit due to ischemic stroke.
The ACTIsSIMA (“Allogeneic Cell Therapy for Ischemic Stroke to Improve Motor Abilities”) trial will investigate the effects of SB623 cells in patients who have experienced an ischemic stroke in the previous six months to five years and continue to suffer from chronic motor disability. When administered into neural tissue, SB623 cell therapy is designed to promote recovery from injury by triggering the brain’s natural regenerative ability. This trial follows a Phase 1/2a clinical trial of SB623 cell implantation which suggested the treatment’s potential to improve motor function following an ischemic stroke. You can review the study at clinicaltrials.gov (the U.S. National Institutes of Health Clinical Trials website).
If you are interested in finding out whether you qualify for this or similar stroke clinical trials, please complete the online questionnaire at http://stemcellstudy.ucsf.edu/.
Traumatic Brain Injury
SanBio is also conducting a Phase 2 clinical trial to evaluate the safety and efficacy of the use of SB623 to treat Traumatic Brain Injury.
The STEMTRA (“Study of Modified Stem Cells in Traumatic Brain Injury”) trial will examine the effects of SB623 cells in patients with chronic deficits resulting from traumatic brain injury. The study is a global study conducted across approximately 25 clinical trial sites throughout the United States and five sites in Japan. Total enrollment is expected to reach 52 patients.
Patients must be at least 12 months post injury and have persistent motor impairments.
You can review the study at clinicaltrials.gov.
If you are interested in finding out whether you qualify for the new trial, please complete the online questionnaire at http://tbistemcellstudy.ucsf.edu/.